As of September 18, 2026, the stock is trading at ₹851.9, with a daily technical stance indicating a bullish trend. This is supported by the price being above key moving averages including the 20-day Exponential Moving Average (EMA) at ₹830.07 and the 200-day Simple Moving Average (SMA) at ₹797.61. The daily Supertrend indicator is also bullish. However, the monthly timeframe presents a conflicting signal, showing a bearish trend with the price below the monthly EMA of ₹966.05 and the Supertrend at ₹1240.74. The weekly timeframe shows a bullish Supertrend, but the price is below the weekly EMA of ₹872.97.

The stock is currently positioned near its nearest resistance levels, with the closest at ₹854.4, approximately 0.29% above the current price. Key support is identified at ₹844.85, about 0.83% below the current price. The stock exhibits a position in the upper range of its 50-day and 252-day price bands, suggesting it has moved higher within these periods. Annualized volatility stands at 33%, with a current drawdown of -45% and a maximum drawdown of -58% observed.

Key patterns observed include an active Outside Bar on the weekly chart and a Morning Star pattern on the daily chart as of September 18, 2026. These patterns, alongside the mixed timeframe signals, suggest a period of potential consolidation or transition. Monitoring the price action around the ₹854.4 resistance and the ₹844.85 support levels will be crucial. A sustained move above resistance could strengthen the daily bullish view, while a break below support might indicate further weakness, especially given the bearish monthly trend.

Investors are advised to monitor HCL Technologies, HDFC Bank, and Sun Pharma on Tuesday, September 15, 2026, due to several significant announcements. HCL Technologies is expected to announce a new artificial intelligence partnership, a development that could shape its future technological offerings. Separately, KEC International has secured new orders, the details of which are anticipated to provide insight into its project pipeline and revenue prospects. Additionally, Dr. Reddy's Laboratories faces an FDA assessment, a crucial event that could impact its product approvals and market access. These corporate events, alongside dividend announcements and other corporate changes, are flagged as key triggers for investor attention.

As of September 18, 2026, Clean Science and Technology (CLEAN) on the NSE has seen a recent price increase. The stock closed at ₹851.9 on September 18, 2026, up from its previous price of ₹828.0. No new filings or news developments were reported as of the observation date. The company's profile and continuing context remain unchanged.

Clean Science and Technology Limited has announced several key developments. On August 31, 2026, the company approved the allotment of 1,601 equity shares under its Employee Stock Option Scheme (ESOS) 2021, increasing the paid-up share capital to ₹10,62,84,121. The company also confirmed the appointment of Mr. Krishnakumar Satyanarain Saboo as an Executive Director (Whole-Time Director) effective August 1, 2026, for a term of 60 months. This appointment was further detailed in filings on September 12, 2026. Shareholders will consider the declaration of a final dividend of ₹4 per equity share for the financial year ended March 31, 2026, with a record date of September 5, 2026. The 23rd Annual General Meeting (AGM) was scheduled for September 12, 2026, to be held via video conference, where resolutions regarding financial statements, dividends, auditor remuneration, director appointments, and non-executive director commissions were to be voted upon.

Clean Science and Technology, listed on the NSE, has shown a consistent upward trend in its revenue from operations over the reported periods. Revenue grew from ₹219.67 crore in Q3 FY2025-26 to ₹249.25 crore in Q4 FY2025-26, and further to ₹268.43 crore in Q1 FY2026-27. This top-line growth has been accompanied by an increase in Profit Before Tax (PBT), which rose from ₹62.57 crore in Q3 FY2025-26 to ₹77.69 crore in Q4 FY2025-26, and reached ₹97.55 crore in Q1 FY2026-27. While revenue and PBT have increased sequentially, the company's "Other Expenses" saw a notable increase from ₹46.24 crore in Q3 FY2025-26 to ₹58.62 crore in Q4 FY2025-26, before declining to ₹50.47 crore in Q1 FY2026-27. Finance costs have remained relatively low, reported at ₹16.70 lakh in Q3 FY2025-26, ₹5 lakh in Q4 FY2025-26, and ₹5.20 lakh in Q1 FY2026-27. The trajectory suggests that revenue growth is translating into improved profitability, though fluctuations in other expenses warrant monitoring. Key areas to watch include the sustained growth in revenue and profit, and the management of operating expenses.

The company's daily and weekly technical trends indicate a constructive setup. The daily trend shows the closing price at ₹851.9 is above both the 20-day and 50-day Exponential Moving Averages (EMAs), with positive slopes observed in the EMAs and Simple Moving Averages (SMAs) over a 5-day period. The Super Trend indicator on the daily chart is also in a bullish direction. Similarly, the weekly trend shows the closing price above the 20-day EMA and the Super Trend indicator in a bullish direction, suggesting upward momentum. The stock has also shown positive returns over shorter periods, including a 9% return in the last 3 months and a 19% return in the last 6 months, though it has experienced a year-to-date return of -1% and a significant drawdown of -45% from its peak.

The company's monthly trend indicators suggest a bearish setup, with the Supertrend indicator at ₹1240.74 and the 20-day Exponential Moving Average at ₹966.05, both significantly above the current closing price of ₹851.9. This indicates potential downward pressure over a longer timeframe. Furthermore, the stock has experienced a substantial drawdown, with a current drawdown of -45% and a maximum drawdown of -58%, highlighting significant past volatility and potential for sharp price declines. The year-to-date return is -1%, and the return since inception is -45%, indicating a challenging performance over these periods.